Get access

Conversion of calcineurin inhibitor treatment to target of rapamycin inhibitor treatment versus continuation of calcineurin inhibitor treatment for liver transplant recipients

  • Protocol
  • Intervention

Authors

  • Luit Penninga,

    Corresponding author
    1. Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Dept 3344 & Surgery and Transplantation, Dept C2122, Copenhagen, Denmark
    • Luit Penninga, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Dept 3344 & Surgery and Transplantation, Dept C2122, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. LP@ctu.rh.dk. luitpenninga@hotmail.com.

    Search for more papers by this author
  • Andre Wettergren,

    1. Copenhagen University Hospital Rigshospitalet, Department of Surgery and Transplantation C2122, Copenhagen, Denmark
    Search for more papers by this author
  • An-Wen Chan,

    1. Toronto, ON, Canada
    Search for more papers by this author
  • Daniel A Steinbrüchel,

    1. Rigshospitalet, Copenhagen University Hospital, Dept 2152, Cardiothoracic Surgery, Copenhagen, Denmark
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

This review aims to assess the benefits and harms of conversion of calcineurin inhibitor treatment to mTor inhibitor treatment compared with continuation of calcineurin inhibitor treatment for liver transplant recipients.